Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Company · United States
Declared costs: €100K+ a year · in the register since 2011
Company · Germany
Declared costs: €2M+ a year · in the register since 2015
Medicinal products for human use · Fluorinated gases regulation
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Baxter · filed 27 Apr 2021 · source
Baxter is a global healthcare company with a leading portfolio of critical care, nutrition, renal, hospital and surgical products and we are driven by our mission to save and sustain lives. We stand ready to partner with EU policy-makers during the on-going process to modernise the EU’s regulatory environment for pharmaceuticals.
Boehringer Ingelheim · filed 27 Apr 2021 · source
Boehringer Ingelheim welcomes the opportunity to input into this consultation. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective and stands for continuous investment in medical innovation to improve the health of humans and animals. As a research-driven biopharmaceutical company, our patient-centric research focus lies on areas of high unmet medical need.
Baxter · filed 28 Jun 2022 · source
Baxter is a leading global pharmaceutical & medical device company committed to delivering life-saving and sustaining products. We have been working with clinicians and hospitals across Europe for years to provide anaesthetic agents (inhaled & intravenous) that allow clinical treatment to be tailored to specific patient needs.
Boehringer Ingelheim · filed 29 Jun 2022 · source
Boehringer Ingelheim (BI) welcomes the European Commission’s ambition to reduce the use of substances with Global Warming Potential (GWP) and to comply with recent international obligations on HFCs (Montreal Protocol).
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.